An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis

Status:
Completed

Trial end date:
2008-07-16

Target enrollment:

Participant gender:

Investigating the safety and tolerability of a p38 inhibitor as monotherapy in subjects who have failed at least 1 DMARD.

Phase 2

Pfizer